BG62685B1 - Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите - Google Patents

Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите Download PDF

Info

Publication number
BG62685B1
BG62685B1 BG100625A BG10062596A BG62685B1 BG 62685 B1 BG62685 B1 BG 62685B1 BG 100625 A BG100625 A BG 100625A BG 10062596 A BG10062596 A BG 10062596A BG 62685 B1 BG62685 B1 BG 62685B1
Authority
BG
Bulgaria
Prior art keywords
mgdf
polypeptide
mpl
cited
polyethylene
Prior art date
Application number
BG100625A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100625A (bg
Inventor
Timothy Bartley
Jakob Bogenberger
Robert Bosselman
Pamela Hunt
Olaf Kinstler
Babru Samal
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/321,488 external-priority patent/US5795569A/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of BG100625A publication Critical patent/BG100625A/bg
Publication of BG62685B1 publication Critical patent/BG62685B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
BG100625A 1994-03-31 1996-05-30 Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите BG62685B1 (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22176894A 1994-03-31 1994-03-31
US25262894A 1994-05-31 1994-05-31
US08/321,488 US5795569A (en) 1994-03-31 1994-10-12 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US34778094A 1994-11-30 1994-11-30
PCT/US1995/003776 WO1995026746A1 (en) 1994-03-31 1995-03-30 Compositions and methods for stimulating megakaryocyte growth and differentiation

Publications (2)

Publication Number Publication Date
BG100625A BG100625A (bg) 1997-04-30
BG62685B1 true BG62685B1 (bg) 2000-05-31

Family

ID=27499246

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100625A BG62685B1 (bg) 1994-03-31 1996-05-30 Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите

Country Status (32)

Country Link
US (1) US5766581A (ro)
EP (3) EP0755263A4 (ro)
JP (2) JP2996415B2 (ro)
KR (2) KR100303810B1 (ro)
CN (2) CN1229385C (ro)
AT (1) ATE169335T1 (ro)
AU (1) AU691606B2 (ro)
BG (1) BG62685B1 (ro)
BR (1) BR9506017A (ro)
CA (1) CA2167090C (ro)
CZ (2) CZ288926B6 (ro)
DE (1) DE69503849T2 (ro)
DK (1) DK0690127T3 (ro)
EE (1) EE9600121A (ro)
ES (1) ES2119250T3 (ro)
FI (1) FI960136A (ro)
GE (1) GEP20002180B (ro)
GR (1) GR3027593T3 (ro)
HK (2) HK1004231A1 (ro)
HU (1) HU218893B (ro)
IL (1) IL113206A0 (ro)
LV (2) LV11783B (ro)
MY (1) MY113048A (ro)
NO (1) NO960111L (ro)
NZ (1) NZ283863A (ro)
PL (1) PL182567B1 (ro)
RO (1) RO115788B1 (ro)
SI (1) SI0690127T1 (ro)
SK (1) SK166695A3 (ro)
TW (3) TW414799B (ro)
WO (1) WO1995026746A1 (ro)
YU (1) YU20095A (ro)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US5696250A (en) 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
WO1996025498A2 (en) * 1995-02-15 1996-08-22 Amgen Inc. Mpl ligand analogs
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DK0885242T3 (da) 1995-06-07 2008-07-14 Glaxo Group Ltd Peptider og forbindelser, der binder til en trombopoietinreceptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
EP0870027A1 (en) * 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
KR100408229B1 (ko) * 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US5914251A (en) * 1996-10-22 1999-06-22 Amgen Inc. Nucleic acid molecules encoding placental-derived growth factors
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
CA2330451A1 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1810832B (zh) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
AU3877800A (en) 1999-03-30 2000-10-16 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
KR100886276B1 (ko) 2000-08-11 2009-03-04 기린 파마 가부시끼가이샤 인산 대사, 칼슘 대사, 석회화 및 비타민 ｄ 대사를조절하는 폴리펩티드 및 그것을 코딩하는 ｄｎａ
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
CA2499625A1 (en) 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
PL219741B1 (pl) * 2002-12-26 2015-07-31 Mountain View Pharmaceuticals Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP4505449B2 (ja) * 2003-02-11 2010-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー 新規二環式化合物および組成物
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004227937B2 (en) * 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
MXPA06002292A (es) 2003-08-28 2006-09-04 Johnson & Johnson Peptidos y compuestos que se unen a un receptor.
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2005063965A1 (de) 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
ES2355642T3 (es) * 2004-07-16 2011-03-29 Nektar Therapeutics Conjugados que comprenden una porcion de gm-csf y un polimero.
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8318153B2 (en) * 2006-06-29 2012-11-27 Nalin David R Method of medically treating an individual
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
KR101546563B1 (ko) 2008-12-09 2015-08-28 할로자임, 아이엔씨 연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
CN102245675B (zh) 2008-12-16 2013-08-14 道康宁公司 硅氧烷的制备
US20110294733A1 (en) 2009-01-20 2011-12-01 Hanall Biopharma Co., Ltd. Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
ES2605593T3 (es) 2009-05-29 2017-03-15 Novartis Ag Métodos de administración de compuestos agonistas de trombopoyetina
IN2012DN03219A (ro) 2009-09-17 2015-10-23 Baxter Healthcare Sa
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
SG11201401797TA (en) 2011-10-24 2014-09-26 Halozyme Inc Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5128449A (en) * 1988-07-05 1992-07-07 The University Of Tennessee Research Corporation Polypeptide and a method for its production
US5258324A (en) * 1988-09-21 1993-11-02 Meiji Seika Kaisha, Ltd. Megakaryocyte colony stimulating factor and process for its preparation
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
EP0466780A4 (en) * 1989-04-03 1992-08-26 Genetics Institute, Inc. Megakaryocyte growth promoting activity
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
ATE144780T1 (de) * 1989-08-08 1996-11-15 Genetics Inst Megakaryocytopoietischer faktor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
EP0672684A1 (en) * 1990-05-31 1995-09-20 Meija Seika Kabushiki Kaisha, Ltd. Novel megakaryocyte colony stimulating factor and production thereof
EP0540575A4 (en) * 1990-07-02 1994-06-08 Hipple Cancer Res Center Human meg-csf protein and methods
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU639378B2 (en) * 1990-10-05 1993-07-22 Systemix, Inc. Megakaryocyte and platelet growth, production and composition
JPH05503302A (ja) * 1990-10-12 1993-06-03 アムジエン・インコーポレーテツド 巨核球成熟因子
WO1992007074A1 (fr) * 1990-10-19 1992-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives
CA2073177A1 (en) * 1990-12-28 1992-06-29 Shuhei Kondo Megakaryocyte potentiator and method for producing the same
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04295500A (ja) * 1991-03-26 1992-10-20 Asahi Chem Ind Co Ltd 新規な巨核球増幅因子とその製法
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
WO1993000433A1 (en) * 1991-06-28 1993-01-07 New England Deaconess Hospital A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
AU3463493A (en) * 1992-02-07 1993-09-03 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
CA2169173C (en) * 1994-02-14 2002-10-15 Kenneth Kaushansky Methods for stimulating erythropoiesis using thrombopoietin
JPH09508797A (ja) * 1994-02-14 1997-09-09 ザイモジェネティクス，インコーポレイティド 造血タンパク質及びそれを製造するための材料及び方法
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
WO1995026746A1 (en) 1995-10-12
CA2167090A1 (en) 1995-10-12
TW414799B (en) 2000-12-11
US5766581A (en) 1998-06-16
PL182567B1 (pl) 2002-01-31
JP2996415B2 (ja) 1999-12-27
HK1004231A1 (en) 1998-11-20
SK166695A3 (en) 1997-02-05
EE9600121A (et) 1997-04-15
EP0690127B1 (en) 1998-08-05
AU2230895A (en) 1995-10-23
JP3485842B2 (ja) 2004-01-13
CZ288890B6 (cs) 2001-09-12
LV12275A (lv) 1999-05-20
DE69503849T2 (de) 1999-04-01
HU9600059D0 (en) 1996-03-28
EP0755263A1 (en) 1997-01-29
LV11783B (en) 1997-12-20
YU20095A (sh) 1998-08-14
NO960111D0 (no) 1996-01-10
PL312577A1 (en) 1996-04-29
DE69503849D1 (de) 1998-09-10
GEP20002180B (en) 2000-07-25
FI960136A0 (fi) 1996-01-11
CN1322759A (zh) 2001-11-21
CN1103782C (zh) 2003-03-26
TW565568B (en) 2003-12-11
KR100303810B1 (ko) 2001-12-01
SI0690127T1 (en) 1998-12-31
NO960111L (no) 1996-09-24
BR9506017A (pt) 1997-10-14
EP0755263A4 (en) 2005-02-09
LV11783A (lv) 1997-06-20
EP0675201A1 (en) 1995-10-04
MY113048A (en) 2001-11-30
CZ350595A3 (en) 1997-01-15
AU691606B2 (en) 1998-05-21
CA2167090C (en) 2002-05-14
CZ288926B6 (cs) 2001-09-12
EP0690127A1 (en) 1996-01-03
NZ283863A (en) 1997-12-19
GR3027593T3 (en) 1998-11-30
CN1229385C (zh) 2005-11-30
ES2119250T3 (es) 1998-10-01
CN1137757A (zh) 1996-12-11
FI960136A (fi) 1996-03-11
DK0690127T3 (da) 1999-05-03
HK1041275A1 (en) 2002-07-05
TW496870B (en) 2002-08-01
MX9600206A (es) 1998-11-30
ATE169335T1 (de) 1998-08-15
HUT74257A (en) 1996-11-28
IL113206A0 (en) 1995-06-29
LV12275B (en) 1999-08-20
KR100203824B1 (ko) 1999-06-15
BG100625A (bg) 1997-04-30
RO115788B1 (ro) 2000-06-30
HU218893B (hu) 2000-12-28
JP2000103799A (ja) 2000-04-11
JPH10510980A (ja) 1998-10-27
HK1041275B (zh) 2006-07-28

Similar Documents

Publication Publication Date Title
BG62685B1 (bg) Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите
US5795569A (en) Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
JP4332163B2 (ja) Ｍｐｌ受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体
CA2178752C (en) N-terminally chemically modified protein compositions and methods
EP0442724A2 (en) Modified hIL-6
CA2181566C (en) Compositions and methods using unbound mpl receptor for stimulating platelet production
EP0811064A2 (en) Mpl ligand analogs
AU727978B2 (en) MPL ligand analogs
CN101142234A (zh) 结合红细胞生成素受体的新肽
RU2158603C2 (ru) Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
WO2020092505A1 (en) Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
TWI327149B (en) Peptides and related compounds having thrombopoietic activity
RO118299B1 (ro) Polipeptida trombopoietina, secventa adn care o codifica, procedeu pentru prepararea polipeptidei trombopoietine si compozitie farmaceutica cu aceasta
MXPA96000206A (en) Compositions and methods to stimulate the growth and differentiation of the megacarioci
PL183631B1 (pl) Pochodna polipeptydu stanowiącego czynnik wzrostu i rozwoju megakariocytów-(polipeptydu MGDF), sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca taką pochodną